SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

AGHAZADEH TABRIZI, Mojgan
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.596
EU - Europa 7.201
AS - Asia 6.493
SA - Sud America 1.135
AF - Africa 163
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 9
Totale 28.609
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.329
SG - Singapore 2.252
FI - Finlandia 2.170
DE - Germania 2.063
CN - Cina 1.810
BR - Brasile 902
VN - Vietnam 687
UA - Ucraina 650
HK - Hong Kong 547
RU - Federazione Russa 540
TR - Turchia 515
GB - Regno Unito 465
IT - Italia 426
SE - Svezia 261
FR - Francia 237
IN - India 138
CA - Canada 126
PL - Polonia 119
JP - Giappone 112
AR - Argentina 108
MX - Messico 102
BD - Bangladesh 94
ZA - Sudafrica 67
IQ - Iraq 55
ID - Indonesia 51
BE - Belgio 43
NL - Olanda 38
PK - Pakistan 36
ES - Italia 33
CO - Colombia 31
LT - Lituania 29
MA - Marocco 24
UZ - Uzbekistan 24
CZ - Repubblica Ceca 23
EC - Ecuador 22
AE - Emirati Arabi Uniti 20
SA - Arabia Saudita 17
CL - Cile 16
EG - Egitto 16
KE - Kenya 15
VE - Venezuela 15
AT - Austria 14
IL - Israele 14
MY - Malesia 14
KR - Corea 13
TW - Taiwan 12
AU - Australia 11
PH - Filippine 11
PY - Paraguay 11
SK - Slovacchia (Repubblica Slovacca) 11
TN - Tunisia 11
BO - Bolivia 10
NP - Nepal 10
PE - Perù 10
DZ - Algeria 9
UY - Uruguay 9
IE - Irlanda 8
AZ - Azerbaigian 7
EU - Europa 7
RO - Romania 7
AL - Albania 6
BG - Bulgaria 6
BH - Bahrain 6
CH - Svizzera 6
CR - Costa Rica 6
IR - Iran 6
KZ - Kazakistan 6
TH - Thailandia 6
GR - Grecia 5
PA - Panama 5
PT - Portogallo 5
ET - Etiopia 4
GT - Guatemala 4
JM - Giamaica 4
KG - Kirghizistan 4
LB - Libano 4
LV - Lettonia 4
MK - Macedonia 4
MN - Mongolia 4
RS - Serbia 4
SV - El Salvador 4
BA - Bosnia-Erzegovina 3
BY - Bielorussia 3
DO - Repubblica Dominicana 3
HN - Honduras 3
HR - Croazia 3
HU - Ungheria 3
JO - Giordania 3
KH - Cambogia 3
MT - Malta 3
AO - Angola 2
CG - Congo 2
CI - Costa d'Avorio 2
KW - Kuwait 2
MD - Moldavia 2
NI - Nicaragua 2
OM - Oman 2
PS - Palestinian Territory 2
QA - Qatar 2
SI - Slovenia 2
Totale 28.577
Salva come PNG Salva come JPEG
Città #
Helsinki 1.978
Singapore 1.521
Ashburn 1.312
Woodbridge 1.266
Fairfield 1.203
Dallas 959
Houston 749
San Jose 699
Jacksonville 698
Ann Arbor 684
Chandler 574
Beijing 543
Hong Kong 525
Santa Clara 517
Seattle 507
Wilmington 497
Cambridge 394
Ho Chi Minh City 224
Izmir 221
Los Angeles 215
Nanjing 186
Munich 176
Ferrara 154
Hanoi 150
Princeton 145
Boardman 144
New York 135
San Diego 111
Lauterbourg 110
Tokyo 109
Warsaw 104
Shanghai 99
São Paulo 94
Milan 89
London 75
Bremen 74
Hefei 65
Shenyang 61
Nanchang 59
Orem 59
Mexico City 57
Turku 56
Tianjin 50
Changsha 49
Montreal 45
Frankfurt am Main 44
Hebei 44
San Mateo 43
Brooklyn 41
Chicago 40
Atlanta 38
Brussels 38
Falkenstein 38
Jiaxing 38
Johannesburg 37
Denver 33
Haiphong 33
Chennai 32
Phoenix 31
Moscow 30
Dong Ket 29
Falls Church 29
Stockholm 29
Toronto 29
Council Bluffs 28
Dearborn 28
Rio de Janeiro 28
Baghdad 27
Jinan 27
Philadelphia 27
Buffalo 25
Da Nang 25
Guangzhou 25
Redwood City 25
Poplar 24
Amsterdam 23
Zhengzhou 23
Mountain View 22
Addison 21
Boston 21
Brasília 21
San Francisco 21
The Dalles 21
Curitiba 20
Kunming 20
Ankara 19
Belo Horizonte 19
Mumbai 19
Tashkent 18
Jakarta 17
Manchester 16
Brno 15
Columbus 15
Hangzhou 15
Orange 15
Auburn Hills 14
Bexley 14
Indiana 14
Washington 14
Biên Hòa 12
Totale 19.156
Salva come PNG Salva come JPEG
Nome #
1,3-Dipropyl-8-(1-phenylacetamide-1H-pyrazol-3-yl)-xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists 3.087
Medicinal Chemistry, Pharmacology, and Clinical Implications of TRPV1 Receptor Antagonists 328
Handbook of Cannabis and Related Pathologies 323
A3 Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy 308
A glance at adenosine receptors: Novel target for antitumor therapy 304
A3 adenosine receptor antagonists: History and future perspectives 283
Synthesis and Structure Activity Relationship Investigation of Triazolo[1,5-a]pyrimidines as CB2 Cannabinoid Receptor Inverse Agonists 280
A [3+2] nitrile oxide intermolecular cycloaddition approach to 4,5-dihydro-3(2H)-furanone and 3(2H)-furanone ring systems: application to the formal synthesis of (±)-ascofuranone and geiparvarin. 277
The A3 adenosine receptor: history and perspectives 275
Design, synthesis, and biological evaluation of novel 2-((2-(4-(substituted)phenylpiperazin-1-yl)ethyl)amino)-5'-N-ethylcarboxamidoadenosines as potent and selective agonists of the A2A adenosine receptor 272
A synthetic approach for the preparation of rigid analogs of 1,3-dipropyl-7-methyl-8-aryl/heteroarylstyryl xanthines 263
Design and Synthesis of Potent in Vitro and in Vivo Anticancer Agents Based on 1-(3’,4’,5’-Trimethoxyphenyl)-2-Aryl-1H-Imidazole 261
Synthesis and biological evaluation of 2-and 3-aminobenzo[b]thiophene derivatives as antimitotic agents and inhibitors of tubulin polymerization 260
7-Substituted-pyrrolo[3,2-d]pyrimidine-2,4-dione derivatives as antagonists of the transient receptor potential ankyrin 1 (TRPA1) channel: A promising approach for treating pain and inflammation 256
Adenosine receptors and human melanoma 253
Allosteric modulators for the A1-adenosine receptor 249
Design, synthesis, DNA binding, and biological evaluation of water-soluble hybrid molecules containing two pyrazole analogues of the alkylating cyclopropylpyrroloindole (CPI) subunit of the antitumor agent CC-1065 and polypyrrole minor groove binders 247
7-Oxo-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxamides as Selective CB2 Cannabinoid Receptor Ligands: Structural Investigations around a Novel Class of Full Agonists 245
[H-3]-MRE 2029-F20, a selective antagonist radioligand for the human A(2B) adenosine receptors 244
N-6-[(Hetero)aryl/(cyclo)alkyl-carbamoyi-methoxy-phenyl]-(2chloro)-5 '-N-ethylearboxamido-adenosines: The first example of adenosine-related structures with potent agonist activity at the human A(2B) adenosine receptor 237
DNA minor groove binders as potential antitumor and antimicrobial agents 236
New 2-heterocyclyl-imidazo[2,1- i ]purin-5-one derivatives as potent and selective human A 3 adenosine receptor antagonists 236
Allosteric enhancers for A(1) adenosine receptor 235
New heterocyclic ligands for the adenosine receptors P1 and for the ATP receptors P2. 234
Design, synthesis and in vitro cytotoxicity of a cis-dichloroplatinum(II) complex linked to the minor groove binder stallimycin 232
Pyrazolo [4,3-e][1,2,4]triazolo[1,5-c]pyrimidine template: Organic and medicinal chemistry approach 229
Blockade of A2A receptors plus L-DOPA after nigrostriatal lesion results in GAD67 mRNA changes different from L-DOPA alone in the rat globus pallidus and substantia nigra reticulata 229
Synthesis and biological effects of a new series of 2-amino-3-benzoylthiophenes as allosteric enhancers of A1-adenosine receptor 228
Adenosine Receptor Antagonists: Translating Medicinal Chemistry and Pharmacology into Clinical Utility 225
Pyrazole phenylcyclohexylcarbamates as inhibitors of human fatty acid amide hydrolases (FAAH) 223
Novel 8-heterocyclyl xanthine derivatives in drug development - An update 222
Hybrid molecules between distamycin A and active moieties of antitumor agents 221
From tyrosine to glycine: Synthesis and biological activity of potent antagonists of the purinergic P2X(7) receptor 220
One-pot reaction to obtain N,N'-disubstituted guanidines of pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine scaffold as human A3 adenosine receptor antagonists 220
Hybrid molecules based on distamycin A as potential antitumor agents 218
Synthesis and preliminary biological evaluation of new anti-tubulin agents containing different benzoheterocycles 217
Geiparvarin analogs. 2. Synthesis and cytostatic activity of 5-(4-arylbutadienyl)-3(2H)-furanones and of N-substituted 3-(4-oxo-2-furanyl)-2-buten-2-yl carbamates. 215
New heterocyclic ligands for the adenosine receptors P1 and for the ATP receptors P2 214
Synthesis of a new series of pyrazolo[1,5-a]pyrimidines structurally related to zaleplon 211
Biological effects of novel 2-amino-3-naphthoylthiophenes as allosteric enhancers of the A1 adenosine receptors 210
Synthesis and biological evaluation of 2-(3 ',4 ',5 '-trimethoxybenzoyl)-3-amino 5-aryl thiophenes as a new class of tubulin inhibitors 209
Structure-activity relationships around the KN-62, a potent antagonist of the P2X(7)receptor 208
Structure-activity relationship studies of a new series of imidazo[2,1-f] purinones as potent and selective A3 adenosine receptor antagonists 207
Microwave-assisted synthesis of thieno[2,3-c]pyridine derivatives as a new series of allosteric enhancers at the adenosine A(1) receptor 207
Modulation of metalloproteinase-9 in U87MG glioblastoma cells by A3 adenosine receptors 207
Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A(2B) adenosine receptor antagonists 206
Discovery and Optimization of a Series of 2-Aryl-4-Amino-5-(3 ',4 ',5 '-trimethoxybenzoyl)Thiazoles as Novel Anticancer Agents 206
Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines and linked Heterocycles as template for the adenosine receptor antagonism: Medicinal chemistry approach and sar considerations 205
Design, synthesis and growth inhibition activity of bis-epoxyethyl derivatives of stallimycin modified on the amidino moiety 203
Synthesis of conformationally constrained analogues of KN62, a potent antagonist of the P2X7-receptor 201
Water-Soluble Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines as Human A3 Adenosine Receptor Antagonists 201
Synthesis and Biological Evaluation of Novel Allosteric Enhancers of the A1 Adenosine Receptor Based on 2-Amino-3-(4’-Chlorobenzoyl)-4-Substituted-5-Arylethynyl Thiophene 199
Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease 197
Synthesis and biological evaluation of 2-amino-3-(3',4',5'-trimethoxyphenylsulfonyl)-5-aryl thiophenes as a new class of antitubulin agents 196
Geiparvarin Analogs. 3. Synthesis and cytostatic activity of 3(2H)-furanone and 4,5-dihydro-3(2H)-furanone congeners of geiparvarin, containing a geraniol-like fragment in the side chain 195
Recent developments in the field of adenosine receptor ligands. 195
A structural study of new potent and selective antagonists to the A(2B) adenosine receptor 195
Pharmacological characterization of novel adenosine ligands in recombinant and native human A2B receptors 195
Recent improvements in the development of A2B adenosine receptor agonists 194
Synthesis and Biological Evaluation of 1-Methyl-2-(3’,4’,5’-Trimethoxybenzoyl)-3-Amino Indoles as a New Class of Antimitotic Agents and Tubulin Inhibitors 192
Medicinal chemistry, pharmacology, and potential therapeutic benefits of cannabinoid CB2receptor agonists 192
Pyrazolotriazolopyrimidine derivatives sensitize melanoma cells to the chemiotherapic drugs: taxol and vindesine. 190
Microwave-assisted synthesis of substituted 2,4-diarylthiazoles and their evaluation as anticancer agents 188
Recent developments in A2B adenosine receptor ligands 188
Recent developments in the field of A(2A) and A(3) adenosine receptor antagonists 186
Synthesis and biological evaluation of 2-amino-3-(4-chlorobenzoyl)-4-[(4- arylpiperazin-1-yl)methyl]-5-substituted-thiophenes. Effect of the 5-modification on allosteric enhancer activity at the A1 adenosine receptor 186
New pyrrolo[2,1-f]purine-2,4-dione and imidazo[2,1-f]purine-2,4-dione derivatives as potent and selective human A(3) adenosine receptor antagonists 185
New 2-arylpyrazolo[4,3-c]quinoline derivatives as potent and selective human A(3) adenosine receptor antagonists 182
Synthesis, radiolabeling, and preliminary biological evaluation of [H-3]-1-[(S)-N,O-bis-(isoquinolinesulfonyl)-N-methyl-tyrosyl]-4-(o-tolyl )-piperazine, a potent antagonist radioligand for the P2X(7) receptor 181
New strategies for the synthesis of A(3) adenosine receptor antagonists 181
MODULATION OF MMP-9 IN U87MG GLIOBLASTOMA CELLS BY A3 ADENOSINE RECEPTORS 181
Hybrid molecules containing benzo[4,5]imidazo[1,2-d][1,2,4]thiadiazole and alpha-bromoacryloyl moieties as potent apoptosis inducers on human myeloid leukaemia cells 180
Preparation of substituted purinylpyrazolylacetamides as adenosine A2B receptor antagonists. 180
New 2-arylpyrazolo[4,3-c]quinoline derivates as potent and selective human A3 adenosine receptor antagonists 178
New synthesis of diazepino[3,2,1-ij]quinoline and pyrido[1,2,3-de] quinoxalines via addition-elimination followed by cycloacylation 177
Recent improvements in the development of A2B adenosine receptor agonists 176
Design, synthesis, and biological evaluation of C-9- and C-2-substituted pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c] pyrimidines as new A(2A) and A(3) adenosine receptors antagonists 175
Pharmacological characterization of novel adenosine ligands in recombinant and native human A2B receptors 174
Blockade of globus pallidus adenosine A2A receptors displays antiparkinsonian activity in 6-hydroxydopamine-lesioned rats treated with D 1 or D2 dopamine receptor agonists 173
Synthesis and biological evaluation of novel N-6-[4-(substituted) sulfonamidophenylcarbamoyl]adenosine-5 '-uronamides as A(3) adenosine receptor agonists 170
Concise Synthesis and Biological Evaluation of 2-Aroyl-5-Amino Benzo[b]thiophene Derivatives As a Novel Class of Potent Antimitotic Agents 169
Pharmacological characterization of novel adenosine ligands in recombinant and native human A2B receptors 167
Cytotoxic drugs regulate VEGF and IL-8 expression in human melanoma cells by A2A and A3 adenosine receptors. 166
Recent improvements in the field of A(3) adenosine receptor ligands 165
Preparation of fused purine derivatives as adenosine A3 receptor modulators. 164
Allosteric enhancers of A1 adenosine receptors: State of the art and new horizons for drug development 164
Involvement of globus pallidus in the antiparkinsonian effects of adenosine A2A receptor antagonists 163
Synthesis and biological evaluation of 2-substituted-4-(3 ',4 ',5 '-trimethoxyphenyl)-5-aryl thiazoles as anticancer agents 163
Preparation of fused purine derivatives as adenosine A3 receptor modulators. 161
Recent developments in the field of adenosine receptor ligands 159
Dopamine and adenosine receptor interaction as basis for the treatment of Parkinson's disease 158
Structure-activity relationships of 2-amino-3-aroyl-4-[(4-arylpiperazin-1- yl)methyl]thiophenes. Part 2: Probing the influence of diverse substituents at the phenyl of the arylpiperazine moiety on allosteric enhancer activity at the A 1 adenosine receptor 157
Modulation of MMP-9 in U87MG glioblastoma cells by A3 adenosine receptors. 157
Design, synthesis and biological evaluation of hybrid molecules containing conjugated styryl ketone and α-bromoacryloyl moieties 155
Antinociceptive effects of the selective CB2 agonist MT178 in inflammatory and chronic rodent pain models. 155
Discovery of 1,5-Diphenylpyrazole-3-Carboxamide Derivatives as Potent, Reversible, and Selective Monoacylglycerol Lipase (MAGL) Inhibitors 155
Ligands for A(2B) adenosine receptor subtype 154
New pyrrolo [2,1-f] purine-2,4-dione and Imidazo[2,1-f]purine-2,4-dione derivates as potent and selective human A3 adenosine receptor antagonists 149
Pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine ligands, new tools to characterize A(3) adenosine receptors in human tumor cell lines 147
Role of strong intramolecular N-H...N hydrogen bonds in determining the conformation of adenosine-receptors antagonists 144
Totale 23.540
Salva come PNG Salva come JPEG
Categoria #
all - tutte 100.796
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 2.447
Totale 103.243
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021609 0 0 0 0 0 0 0 0 0 267 210 132
2021/20221.546 58 144 147 53 98 78 79 53 57 118 150 511
2022/20231.389 142 82 26 183 291 209 58 109 171 10 67 41
2023/2024752 67 94 43 28 56 111 38 74 13 10 11 207
2024/20253.165 65 101 246 128 370 336 120 189 405 315 474 416
2025/202610.862 906 586 1.351 1.112 1.268 692 1.001 454 2.561 931 0 0
Totale 28.784